Share on StockTwits

Investment analysts at Canaccord Genuity began coverage on shares of Zafgen (NASDAQ:ZFGN) in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $36.00 price target on the stock. Canaccord Genuity’s target price points to a potential upside of 102.93% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities initiated coverage on shares of Zafgen in a research note on Tuesday, July 29th. They set an “outperform” rating and a $31.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Zafgen in a research note on Wednesday, July 23rd. They set an “outperform” rating and a $35.00 price target on the stock. Finally, analysts at Cowen and Company initiated coverage on shares of Zafgen in a research note on Monday, July 14th. They set an “outperform” rating and a $45.00 price target on the stock.

Zafgen (NASDAQ:ZFGN) traded up 0.51% during mid-day trading on Wednesday, hitting $17.83. 19,997 shares of the company’s stock traded hands. Zafgen has a 1-year low of $17.06 and a 1-year high of $21.01. The stock has a 50-day moving average of $18.55 and a 200-day moving average of $18.65. The company’s market cap is $388.8 million.

Zafgen (NASDAQ:ZFGN) last announced its earnings results on Wednesday, August 13th. The company reported ($2.96) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.28) by $2.68. On average, analysts predict that Zafgen will post $-6.96 earnings per share for the current fiscal year.

Zafgen, Inc is a biopharmaceutical company. The Company is engaged in improving the health and well-being of patients affected by obesity.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.